"Amgen's Wegovy: Promising Early Data for Taperable Weight-Loss Drug"
Amgen is testing a unique strategy with its obesity drug candidate, MariTide, to see if it can be tapered down to lower or less frequent doses over time, potentially providing longer-lasting weight loss than existing popular obesity drugs like Wegovy and Zepbound. The ongoing Phase 2 trial aims to titrate participants up on MariTide and then transition them to a less intensive dosing regimen to assess the drug's effectiveness, challenging the current expectation of lifelong consistent dosing for obesity drugs.